Superworth

Alnylam Pharmaceuticals forward PE ALNY

Share price divided by analysts' consensus earnings for the next twelve months, since 2025.

Today, Oct 23, 2026
26.7×
Peer median
35.1×

Alnylam Pharmaceuticals' forward PE is 26.7× as of Oct 23, 2026.

The median for 10 biotech stocks of a similar size is 35.1×.

Forward PE over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far26.7×24.5×74.0×
202574.1×73.5×163×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

CompanyForward PE
ALNYAlnylam Pharmaceuticals26.7×
UTHRUnited Therapeutics22.0×
INCYIncyte49.5×
ONCBeOne Medicines48.1×
EXELExelixisn/m
NBIXNeurocrine Biosciencesn/m
HALOHalozyme Therapeuticsn/m
TECHBIO-TECHNEn/m
REGNRegeneron Pharmaceuticals12.6×
RGENRepligenn/m
KRYSKrystal Biotechn/m
Peer median35.1×

Where Alnylam Pharmaceuticals ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.